ABBOTT's DEPAKOTE APPROVAL FOR ACUTE TREATMENT OF MANIC EPISODES RECOMMENDED BY FDA COMMITTEE; COMPANY IS CONDUCTING RELAPSE PREVENTION TRIAL
Approval of Abbott's Depakote (NDA 20-320) for the acute treatment of manic episodes in bipolar disorder was recommended unanimously by FDA's Psychopharmacologic Drugs Advisory Committee on Feb. 6. The indication for mania, acknowledged to be common clinical practice, would be the third for the oral anti- epileptic divalproex sodium.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth